Autoantibodies generated against peptidyl citrullines are found in around 70% of RA patients and are often used for diagnostic and predictive purposes, whereby the presence of ACPA at early diagnosis is correlated with disease progression and joint damage in human patients [23]. The gene discussed is PRTN3; the disease is rheumatoid arthritis.